HVO Stock Overview
hVIVO plc operates as a pharmaceutical service and contract research company.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
hVIVO plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.28 |
| 52 Week High | UK£0.32 |
| 52 Week Low | UK£0.14 |
| Beta | 1.01 |
| 1 Month Change | 0% |
| 3 Month Change | -1.72% |
| 1 Year Change | 66.18% |
| 3 Year Change | -28.75% |
| 5 Year Change | n/a |
| Change since IPO | 319.12% |
Recent News & Updates
Recent updates
hVIVO plc's (LON:HVO) Intrinsic Value Is Potentially 28% Above Its Share Price
Jan 26
Improved Revenues Required Before hVIVO plc (LON:HVO) Stock's 26% Jump Looks Justified
Jan 03At UK£0.20, Is hVIVO plc (LON:HVO) Worth Looking At Closely?
Nov 30A Piece Of The Puzzle Missing From hVIVO plc's (LON:HVO) Share Price
Jun 14A Look At The Intrinsic Value Of hVIVO plc (LON:HVO)
Feb 01Should You Investigate hVIVO plc (LON:HVO) At UK£0.11?
Dec 20Is There An Opportunity With Open Orphan Plc's (LON:ORPH) 41% Undervaluation?
Sep 13Are Investors Undervaluing Open Orphan plc (LON:ORPH) By 44%?
Jun 02Introducing Open Orphan (LON:ORPH), The Stock That Soared 388% In The Last Year
Feb 15How Much Of Open Orphan plc (LON:ORPH) Do Insiders Own?
Dec 23Calculating The Fair Value Of Open Orphan plc (LON:ORPH)
Nov 18Shareholder Returns
| HVO | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 3.3% | 1.9% | 2.3% |
| 1Y | 66.2% | -41.7% | 0.6% |
Return vs Industry: HVO exceeded the UK Life Sciences industry which returned -41.1% over the past year.
Return vs Market: HVO exceeded the UK Market which returned 0.3% over the past year.
Price Volatility
| HVO volatility | |
|---|---|
| HVO Average Weekly Movement | 7.1% |
| Life Sciences Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: HVO has not had significant price volatility in the past 3 months.
Volatility Over Time: HVO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 274 | Mo Khan | www.hvivo.com |
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations.
hVIVO plc Fundamentals Summary
| HVO fundamental statistics | |
|---|---|
| Market cap | UK£193.91m |
| Earnings (TTM) | UK£16.12m |
| Revenue (TTM) | UK£58.67m |
12.0x
P/E Ratio3.3x
P/S RatioIs HVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVO income statement (TTM) | |
|---|---|
| Revenue | UK£58.67m |
| Cost of Revenue | UK£45.63m |
| Gross Profit | UK£13.04m |
| Other Expenses | -UK£3.08m |
| Earnings | UK£16.12m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.024 |
| Gross Margin | 22.22% |
| Net Profit Margin | 27.47% |
| Debt/Equity Ratio | 0% |
How did HVO perform over the long term?
See historical performance and comparison